Dr. Shagisultanova, is a breast medical oncologist and physician-scientist. Her clinical practice focuses on the care of patients with complex and advanced breast cancers, including HER2-positive and hormone receptor positive disease, hereditary breast cancer, and breast cancer in young women. She is actively involved in clinical trials, offering patients access to emerging targeted therapies and innovative treatment combinations.
Dr. Shagisultanova’s research centers on translational oncology, with a particular emphasis on developing novel targeted and chemotherapy-sparing regimens. Her work explores mechanisms of therapeutic resistance, especially interactions between estrogen receptor and HER2 signaling pathways, and aims to design more effective, less toxic combination therapies. By integrating laboratory discoveries with early-phase clinical trials, she works to advance personalized treatment strategies and improve outcomes for patients with breast cancer.